Hence, apart from CEA, CA19-9, and other commonly used biomarkers of CRC, serum level of IGF-1 and the ratio of IGF-1 to IGFBP3 are potential novel tumor makers with diagnostic and prognostic relevance in patients with coexisting CRC and T2DM. The gene discussed is IGF1; the disease is colorectal carcinoma.